To further standardize the development of Laos' cross-border pharmaceutical industry, strengthen drug quality supervision and deepen practical cooperation in the medical and pharmaceutical sector, leaders of the Lao Ministry of Health and relevant industry experts recently paid a special inspection visit to Laos Qizhouke International Pharmaceutical Group (hereinafter referred to as Qizhouke Group). They gained in-depth insights into the enterprise's operation and management, pharmaceutical supply chain development, compliant business practices and market layout. Relevant principals of Qizhouke Group accompanied the whole inspection.

During the inspection, the delegation from the Ministry of Health successively visited the overseas warehouse in Boten, drug inspection area and operation center of Qizhouke Group in Laos. They inspected the warehouse environment, constant-temperature storage facilities and drug sorting procedures on site, and enquired in detail about the construction of the drug traceability system and the implementation of quality inspection standards.

At the drug inspection area, the leaders checked the operation of various testing equipment and learned about the enterprise's three-level quality inspection mechanism covering overseas pharmaceutical factories, overseas warehouses and end consumers. They showed keen interest in the blockchain-based drug traceability technology adopted by the group, and verified the full-process traceability information of drugs by scanning QR codes on the spot.

They spoke highly of the triple guarantee system consisting of original factory traceability codes, constant-temperature storage and blockchain data certification for every medicine box. It is acknowledged that this mechanism effectively blocks counterfeit and substandard drugs from entering the market and fully safeguards people's medication safety.

At the symposium, the person-in-charge of Qizhouke Group gave a detailed report to the inspection team on the company’s development history, core strengths and international layout.

Having been deeply engaged in the cross-border pharmaceutical industry for 14 years, Qizhouke Group has built law-compliant cross-border pharmaceutical channels relying on the mature global supply chain system of India Gaoshi Group. Headquartered in Vientiane, capital of Laos, it enjoys convenient transportation adjacent to Vientiane Station of the China-Laos Railway with complete supporting logistics facilities. It has expanded its business to the Middle East, South America, Southeast Asia and other international markets, serving over 3 million households worldwide, more than 60 percent of which are users in counties and grassroots areas.

As a leading grassroots enterprise in the field of cross-border generic drugs, the group adopts a dual-warehouse layout featuring the Boten Overseas Warehouse in Laos and bonded warehouses in Hainan and Guangzhou. Located merely 200 meters away from the Chinese border port, the Boten warehouse enables nationwide delivery within 5 to 10 working days, effectively bridging the last mile for grassroots people to purchase cross-border medicines.

Furthermore, the group maintains direct partnerships with more than ten pharmaceutical enterprises in India, Laos and other regions. It holds the exclusive general agency right for the first generic drugs of Laos United Pharmaceutical, with over 500 types of generic drugs available. These medicines cover common grassroots prevalent tumors such as lung cancer and liver cancer as well as rare diseases, priced at only one-fifth to one-tenth of original brand drugs, effectively addressing the difficulties and high costs of medication faced by grassroots patients.

After listening to the report attentively, the leaders of the Lao Ministry of Health spoke highly of the achievements made by Qizhouke Group in standardized operation, supply chain construction and grassroots medical services.

They affirmed that as a benchmark enterprise in Laos’ cross-border pharmaceutical sector, Qizhouke Group is well aligned with the development needs of Laos’ healthcare industry. Its operation model featuring affordable prices, standardized safety guarantee and grassroots-oriented services not only provides cost-effective medicines for local people, but also fuels the standardized and modernized development of Laos’ pharmaceutical industry.

In view of the current situation of Laos’ pharmaceutical industry, the leaders pointed out that Laos still relies heavily on imported medicines and needs to improve medicine accessibility. They expressed the hope that Qizhouke Group will give full play to its resource advantages, further enrich drug varieties, deepen cooperation with local pharmaceutical manufacturers and medical institutions in Laos, and boost the localized and standardized development of domestic pharmaceutical production in Laos. Meanwhile, the group shall strictly comply with drug supervision regulations and steadily consolidate the quality and safety barrier of pharmaceuticals.

Both sides also conducted in-depth exchanges on topics including Laos pharmaceutical supervision policies, drug registration application and cross-border pharmaceutical cooperation mechanisms, reaching a number of consensuses.

The person in charge of Qizhouke Group stated that the company will actively respond to the guidance and requirements of the Lao Ministry of Health, adhere to the bottom line of compliant operation, continuously optimize the supply chain system, improve drug quality control standards, strengthen cooperation with local pharmaceutical sectors in Laos, take an active part in the upgrading of Laos' pharmaceutical industry, further deepen China-Laos cross-border pharmaceutical cooperation, and contribute to building a China-Laos health community.

This inspection fully recognizes Qizhouke Group's standardized operation and service capabilities by the Lao Ministry of Health, and also builds a solid bridge for further in-depth cooperation between the two sides. It will further advance the standardized development of Laos' cross-border pharmaceutical industry, enable more high-quality and affordable medicines to benefit the Lao people, and help elevate the medical and healthcare cause of Laos to a new level.